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Abstract
Walker-Warburg syndrome (WWS) is an autosomal recessive multisystem disorder characterized
by complex eye and brain abnormalities with congenital muscular dystrophy (CMD) and aberrant
α-dystroglycan (αDG) glycosylation. Here, we report mutations in the isoprenoid synthase
domain-containing (ISPD) gene as the second most common cause of WWS. Bacterial IspD is a
nucleotidyl transferase belonging to a large glycosyltransferase family, but its role in chordates
has been obscure to date because this phylum does not have the corresponding non-mevalonate
isoprenoid biosynthesis pathway. Knockdown of ispd in zebrafish recapitulates the human WWS
phenotype with hydrocephalus, reduced eye size, muscle degeneration and hypoglycosylated
αDG. These results implicate a role for ISPD in αDG glycosylation to maintain sarcolemma
integrity in vertebrates.
Defective O-linked glycosylation of αDG is the characteristic feature of a clinically and
genetically heterogeneous group of disorders, commonly referred to as
dystroglycanopathies. This group of diseases is characterized by a broad phenotypic
spectrum ranging from severe forms of CMD with eye involvement, cerebral malformations
and intellectual disability including WWS and Muscle Eye Brain disease (MEB), to milder
adult-onset phenotypes without central nervous system involvement such as limb girdle
muscular dystrophy (LGMD) type 2I1. Mutations in six genes, POMT1, POMT2,
POMGnT1, FKTN, FKRP and LARGE, encoding proteins involved in the post-translational
modification of αDG, have been implicated in WWS and other dystroglycanopathies1-10.
Mutations in these six genes represent 35% of WWS incidence, suggesting that additional
WWS genes await discovery. At the milder end of the dystroglycanopathy disease spectrum
single patients have been reported with αDG hypoglycosylation due to a missense mutation
in either the dystroglycan gene (DAG1)11 or the DPM3 gene12, the latter leading to reduced
levels of dolichol-P-mannose donor for O-mannosylation12. The factors determining
dystroglycanopathy phenotypes are not well understood, but may involve the extent of
residual glycosylation of αDG1,13,14 and other proteins15-17. Identifying novel causative
genes will shed light on the pathological mechanisms of WWS and other
dystroglycanopathies.
To identify novel genes that are involved in WWS, we selected a cohort of 59 patients with
idiopathic WWS in whom mutations in the known dystroglycanopathy genes had been
previously excluded. Thirty of these patients, the majority of whom came from
consanguineous families, were genotyped using the Affymetrix GeneChip Human Mapping
250K SNP NspI Array to identify copy number variants (CNVs) and homozygous regions.
SNP haplotyping detected a large number of non-overlapping homozygous regions amongst
these patients, providing support for further genetic heterogeneity in WWS (Supplementary
Fig. 1). Interestingly, the corresponding CNV profiles identified two homozygous deletions
affecting the ISPD gene (patients WWS-160 and WWS-161, Supplementary Fig. 2),
suggesting that ISPD is a strong candidate for WWS, as there were no other overlapping
CNV regions present in the patient cohort. Another family (WWS-25; for pedigree see
Supplementary Fig. 3a) was identified with two siblings and a cousin affected with WWS
who shared a 3.5 Mb homozygous region on chromosome 7p21 containing ten genes
including ISPD (Fig. 1a). One of these siblings was investigated by exome sequencing and
after filtering based on an autosomal recessive pattern of inheritance according to methods
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described previously18, a single homozygous variant was identified in this region of shared
homozygosity. This c.647C>A transversion in exon 3 of ISPD (NM_001101426.3),
predicting a p.Ala216Asp substitution, showed complete segregation in the family, being
present in the homozygous state in the other two affected individuals, in the heterozygous
state in both parental couples and absent in healthy or deceased siblings with another
phenotype.
Next, we sequenced the ten coding exons of ISPD in the WWS patient cohort and identified
missense, nonsense and frameshift mutations in an additional five individuals from five
families (Supplementary Fig. 3). In addition, failure to PCR-amplify exons 3 to 5 in family
WWS-37, suggested the presence of a homozygous intragenic microdeletion, which was
confirmed by quantitative MLPA analysis (data not shown). An overview of all identified
mutations is given in Table 1 and a schematic representation of their localization is shown in
Figure 1a. In summary, mutations affecting ISPD were detected in 9 out of 94 families,
accounting for an overall percentage of 10% (Fig. 1b). All mutations showed a segregation
pattern expected for causative recessive mutations in family members available for testing
and were absent in a control cohort of 3712 haploid genomes. The three nonsense mutations,
p.Arg268*, p.Lys278* and p.Glu396*, are predicted to give rise to nonsense-mediated
mRNA decay or truncation of the protein. The three missense mutations (p.Ala216Asp,
p.Arg126His and p.Ala122Pro) are located within the ISPD domain (Fig. 1a; Supplementary
Fig. 4a), a conserved domain of a large GT-A glycosyltransferase family that also includes
nucleotidyltransferases19. Both p.Ala216Asp and p.Arg126His affect highly conserved
amino acids and are predicted to be damaging by PolyPhen2, whereas p.Ala122Pro is
predicted to be probably damaging. In silico modeling based on an E. coli IspD crystal
structure using the HOPE web server (see URLs) predicted charge and size differences
between the wild-type and mutant amino acids that are likely to affect protein folding and
disruption of the CTP-binding pocket for mutations p.Ala122Pro and p.Arg126His
(Supplementary Fig. 4b).
All affected individuals with ISPD mutations had a severe WWS-like phenotype with only
two out of 11 surviving beyond two years of age with brain anomalies that are more
indicative of MEB (WWS-81 and -163; Supplementary Table 1). Routine cerebral MRI
(Fig. 2a and 2b) showed typical features of cobblestone lissencephaly together with
hydrocephalus, cerebellar hypoplasia and a kinked brainstem. Muscle histology and
immunohistochemistry showed dystrophic changes and clear reduction of glycosylated αDG
by the IIH6 antibody, which recognizes an unknown glyco-epitope on αDG20 (patients from
families WWS-25, -160, and -81) (Fig. 2c-f).
The function of ISPD in vertebrates is unknown. In view of the significant conservation of
protein sequences (65% amino acid similarity) between the zebrafish (Danio rerio) and
human orthologs, we determined the effects of loss of function of zebrafish ispd, which
encodes two isoforms that differ only in their N-termini. To do this, we knocked down both
ispd isoforms with antisense morpholino oligonucleotides (MO), targeting exon-intron
splice sites common to both transcripts (Supplementary Fig. 5). High doses of ispd MO1 (7
ng) caused hydrocephalus and incomplete brain folding in 82% of embryos (n=88) by 48
hours post fertilization (h.p.f.) (Fig. 3a and Supplementary Fig. 6), as well as significantly
reduced eye size reminiscent of microphthalmia in WWS patients (Fig. 3b and 3c). Other
phenotypic features included impaired motility and myotome lesions (data not shown).
Injection of ispd MO2 (3 ng) caused similar morphological abnormalities, assuring the
specificity of both MOs (Supplementary Fig. 7). We looked for structural defects in muscle
fibers by labeling sarcolemma with membrane-localized red fluorescent protein (mRFP) and
filamentous-actin (F-actin) with phalloidin. ispd MO1-injected embryos showed muscle
fiber degeneration by 72 h.p.f. (Fig. 3d) and, in some cases, disruption of myotendinous
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junctions (MTJ; 45%, n=31), exemplified by elongated muscle fibers spanning MTJ (Fig.
3d). Together, these results suggest that zebrafish ispd knockdown embryos recapitulate the
major aspects of human WWS pathology.
Hypoglycosylation of αDG is a diagnostic characteristic of WWS. To test if knockdown of
ispd in zebrafish also affects glycosylation of αDG, we performed western blotting with the
IIH6 antibody20. Compared with control embryos, glycosylated αDG was reduced in ispd
MO1-injected zebrafish embryos (Fig. 4a). Given the similarity of MTJ disruption observed
in ispd MO1-injected embryos and zebrafish laminin mutants21,22, the localization of
laminins was assessed. Despite the severe muscle fiber degeneration, laminins remained
localized to the MTJ in ispd MO1-injected embryos (Fig. 4b). Subsequently, we assessed the
sarcolemma integrity in embryos injected with either ispd MO using Evans blue dye (EBD).
Intact sarcolemma is impermeable to EBD. We found that MTJ-anchored muscle fibers were
infiltrated by EBD before the onset of muscle degeneration at 48 h.p.f. (Fig. 4c and
Supplementary Fig. 7c). Muscle pathology became evident as EBD-infiltrated muscle fibers
retracted during muscle degeneration. The posterior myotome of ispd MO1-injected
embryos was more susceptible to sarcolemma damage than the anterior myotome (Fig. 4c).
As sarcolemma damage was reported in dystrophin-deficient models23,24, we assessed the
immunoreactivity of dystrophin in ispd MO1-injected embryos. No obvious alterations to
dystrophin immunoreactivity were detected (data not shown). Together, these results
demonstrate an important WWS pathogenic mechanism, independent from laminin and
dystrophin, in which loss of Ispd function in zebrafish results in αDG hypoglycosylation
and compromised sarcolemma integrity, preceding muscle fiber degeneration.
In plants, protozoa and some bacteria, ISPD belongs to the non-mevalonate isoprenoid
biosynthesis (MEP) pathway, which is absent in vertebrates25. Prokaryotic IspD has
cytidyltransferase activity using 2-C-methyl-D erythritol as substrate for the synthesis of the
nucleotide sugar CDP-methyl-erythritol. The structurally homologous TarI in Streptococcus
pneumoniae, lacking the MEP pathway, uses ribitol-1-phosphate to produce an activated
nucleotide sugar (CDP-ribitol) used for incorporation in polysaccharides26. Analogous to the
role of DPM3, it is likely that human ISPD synthesises a novel nucleotide sugar, the exact
nature of which remains to be determined. Glycosyltransferases could use such nucleotide-
activated building blocks for incorporation into the αDG O-mannosyl glycan. Intriguingly,
the bacterium Prevotella tannerae expresses a gene (accession number ZP_05736246) with
both IspD and LicD (lipopolysaccharide core D) domains, which may act sequentially in the
post-translational modifications. The LicD domain is also found in the putative
glycosyltransferases, FKTN and FKRP, both involved in the glycosylation of αDG. Thus, it
appears that the ISPD and LicD domains that are both contained in a prokaryotic precursor
protein are dispersed over the vertebrate ISPD and FKTN/FKRP proteins, respectively. We
sought to test the possibility of genetic interactions between these genes. Co-injection of
sub-effective doses of ispd MO1 with fktn or fkrp MO showed a marked increase in the
proportion of embryos with hydrocephalus (68% and 49% respectively, compared with 3%
in control MO and ispd MO1 co-injection; Fig. 4d and Supplementary Fig. 8a). The same
effect was seen using ispd MO2, confirming specificity (Supplementary Fig. 8). Moreover,
glycosylation of αDG is reduced in the embryos co-injected with ispd MO1 and fktn/fkrp
MO as compared to embryos co-injected with ispd MO1 and control MO, and single fktn/
fkrp MO-injected embryos (Fig. 4e). These results support a cooperative interaction between
ispd and fktn/fkrp in αDG glycosylation.
In conclusion, our findings provide evidence for a significant contribution of ISPD
mutations to the prevalence of WWS. We report the identification of ISPD mutations in nine
WWS families. Due to the high frequency of ISPD mutations in this WWS cohort (15% of
pre-screened patients, 10% overall, Fig. 1b), we recommend that ISPD mutation analysis
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should be performed as part of routine molecular diagnostic testing in WWS. With the
identification of ISPD, we can now explain almost 50% of all WWS of our cohort. The
results of homozygosity mapping indicate the existence of several additional loci. Given that
most of the remaining patients represent isolated cases, we anticipate that exome sequencing
will be the strategy of choice to resolve additional genes and to unravel the complex post-
translational modification pathways that are key to normal brain and muscular development.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Overview of genetic data in the patient cohort. (a) Schematic representation of the intragenic
deletions, point mutations and homozygosity mapping data from WWS families with ISPD
mutations. Ideogram of chromosome 7 showing the 3.5 Mb region of common
homozygosity at band 7p21.3 flanked by SNPs rs194034 and rs818323 that was identified in
family WWS-25. The position of three partially overlapping intragenic deletions in ISPD is
indicated above the intron-exon structure of the gene. At the bottom the position of
homozygous and compound heterozygous mutations is shown with respect to the ISPD
protein domain structure. (b) Identified mutations in our total WWS/MEB cohort in number
and percentage per gene. 94 families were available for research and prescreening revealed
mutations in one of the six known genes in 35 families.
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Figure 2.
MR images and muscle staining of patient WWS-160. (a) Axial T1 weighted and (b)
parasagittal T2 cerebral MRIs showing hydrocephalus. (c) Muscle biopsy showed almost
absent αDG glycosylation using IIH6 antibody in muscle in comparison to (d) IIH6 staining
in a normal control muscle biopsy. (e) Spectrin staining in the patient was not visibly
different from (f) normal control spectrin staining. Scale bars, 20 μm.
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Figure 3.
Knockdown of zebrafish ispd recapitulates pathological defects of human WWS. (a)
Compared with uninjected controls, zebrafish embryos injected with ispd MO1 (7 ng)
showed characteristic hydrocephalus (asterisk) by 48 h.p.f. Scale bar, 100 μm. (b) Embryos
injected with ispd MO1 (7 ng) showed microphthalmia by 48 h.p.f. in comparison to
controls; cell membranes were visualized by membrane-localized red fluorescent protein
(mRFP). Scale bar, 100 μm. (c) Eye width measurements in control (297.52±9.06 μm,
n=25) and ispd MO1 (7 ng) injected embryos (230.8±28.35 μm, n=25; ***P= 4.68E-12).
Co-injection of p53 MO (6 ng) with ispd MO1 (6 ng) still resulted in reduced eye size
(260.28 ± 6.86 μm, n=25; ***P= 1.39E-20), suggesting that this phenotype was not a
consequence of MO off-target effects mediated by p53-induced cell death. Error bars
indicate s.d. (d) Control embryos display intact muscle fibers that anchor to chevron-shaped
MTJ. Embryos injected with ispd MO1 (7 ng) showed muscle fiber degeneration by 72 h.p.f.
Retracting muscle fibers were revealed by condensed F-actin (arrows) and collapsed
sarcolemma (visualized by mRFP). Abnormally elongated muscle fibers spanned disrupted
MTJ (arrowheads) in zebrafish embryos lacking Ispd. DAPI indicates nuclei. Scale bar, 100
μm.
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Figure 4.
Hypoglycosylation of αDG and disrupted sarcolemma integrity in ispd MO1-injected
zebrafish embryos. (a) Western blot analysis of microsome pellets and supernatant from
control, ispd MO1 (7 ng) and dag1 MO (5 ng) injected embryos at 48 h.p.f. Compared with
control embryos, ispd MO1-injected embryos showed a reduction of glycosylated αDG
(IIH6; 76-102 kDa) with a slight decrease of ßDG, which is probably a secondary reduction
due to protein instability caused by defective glycosylation of αDG as reported
previously27,28. Both glycosylated αDG and ßDG were almost absent in dag1 MO-injected
embryos. Equal protein loading was demonstrated by Ponceau S (PonS) staining and
unknown glycoproteins detected by IIH6 antibody in all three lanes (<38 kDa). Equivalent
amounts of γ- and acetylated tubulins were detected in corresponding microsome
supernatant. (b) Laminins remained localized at the MTJ in ispd MO1-injected embryos (7
ng). Positive fluorescent signal within degenerated muscle fibers (arrows) was probably due
to disrupted sarcolemma integrity. Scale bar, 50 μm. (c) MTJ-anchored muscle fibers were
infiltrated by EBD in ispd MO1-injected embryos before the onset of muscle degeneration.
Dashed lines indicate MTJ. DIC, differential interference contrast microscopy; ANT,
anterior myotome; PST, posterior myotome. Scale bar, 50 μm. (d) Injection of sub-effective
doses of ispd, fktn, fkrp and control MO together or alone. Increase in the percentage of
embryos with hydrocephalus suggests genetic interactions between ispd, fktn and fkrp. Each
bar represents a combination of two independent experiments, scored blindly according to
criteria exemplified in Supplementary Fig. 8a. n=94–139 embryos. (e) Western blotting with
IIH6 antibody showed a reduction of glycosylated αDG in embryos co-injected with ispd
MO1 and fktn/fkrp MO as compared to control MO and ispd MO1 co-injected embryos, and
single fktn or fkrp MO-injected embryos. As a negative control, almost absent αDG
glycosylation is shown for dag1 MO injected embryos.
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